Gwenn Hansen sold $84k of NRIX
Chief Scientific Officer at Nurix Therapeutics, Inc.. 3,437 shares at an average of $24.31, traded Oct 30, 2024, filed Oct 30, 2024.
Score components
- +15RoleOfficer
- +9Trade size$84k at market
- 0Share of holdings soldSold 6.4% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -8.1%, 3m -18.4%, 6m -52.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001549595-24-000147, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 30, 2024 | MOption exercise Common Stock | +3,207 | $0.00 | $0 | 48,357 | Oct 30, 2024 |
| Oct 30, 2024 | MOption exercise Common Stock | +2,000 | $0.00 | $0 | 50,357 | Oct 30, 2024 |
| Oct 30, 2024 | MOption exercise Common Stock | +3,750 | $0.00 | $0 | 54,107 | Oct 30, 2024 |
| Oct 30, 2024 | SOpen-market sale Common Stock | -3,437 | $24.31 | $84k | 50,670 | Oct 30, 2024 |
| Oct 30, 2024 | MOption exercise Restricted Stock Unitsderivative | -3,207 | $0.00 | $0 | 16,034 | Oct 30, 2024 |
| Oct 30, 2024 | MOption exercise Restricted Stock Unitsderivative | -2,000 | $0.00 | $0 | 12,000 | Oct 30, 2024 |
| Oct 30, 2024 | MOption exercise Restricted Stock Unitsderivative | -3,750 | $0.00 | $0 | 37,500 | Oct 30, 2024 |
Related signals
Other insiders at Nurix Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 1Weak | Nurix Therapeutics, Inc. | Christine Ring Chief Legal Officer | $134k 5,786 shares | -39% | |
| 9Weak | Nurix Therapeutics, Inc. | Christine Ring Chief Legal Officer | $149k 5,787 shares | -39% | |
| 0Weak | Nurix Therapeutics, Inc. | Gwenn Hansen Chief Scientific Officer | $37k 1,452 shares | -1% | |
| 29Weak | Nurix Therapeutics, Inc. | Hans van Houte Chief Financial Officer | $60k 5,402 shares | -13% | |
| 22Weak | Nurix Therapeutics, Inc. | Gwenn Hansen Chief Scientific Officer | $52k 4,308 shares | -6% | |
| 21Weak | Nurix Therapeutics, Inc. | Christine Ring Chief Legal Officer | $46k 3,841 shares | -8% | |
| 29Weak | Nurix Therapeutics, Inc. | Hans van Houte Chief Financial Officer | $52k 4,304 shares | -10% | |
| 30Weak | Nurix Therapeutics, Inc. | Hans van Houte Chief Financial Officer | $70k 6,198 shares | -16% | |
| 21Weak | Nurix Therapeutics, Inc. | Gwenn Hansen Chief Scientific Officer | $39k 3,377 shares | -5% | |
| 27Weak | Nurix Therapeutics, Inc. | Hans van Houte Chief Financial Officer | $28k 2,438 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.